Clearside submits NDA for uveitic macular edema treatment

Clearside Biomedical has submitted a new drug application to the FDA for Xipere, its treatment for macular edema associated with uveitis, according to a press release.
Xipere, a proprietary suspension of triamcinolone acetonide, is designed to be administered to the back of the eye through a suprachoroidal injection.
Earlier this year the company released results of the phase 3 PEACHTREE trial, in which 47% of patients dosed with Xipere, formerly known as CLS-TA, gained at least 15 letters in best corrected visual acuity.
“Based on the data from PEACHTREE, our (Read more...)

Full Story →